The company

Rosemont Pharmaceuticals is the UK’s leading liquid pharmaceuticals business. Its portfolio of oral liquid medicines includes licensed products which are sold into the UK as well as the US, Continental Europe and the Middle East. The business benefits from strong R&D and innovation, and has built a track record of successful new product launches.

The Inflexion difference

With substantial experience in successfully executing carve-outs, we have drawn upon our healthcare expertise to establish Rosemont as a standalone business, including using our digital experience to assist with the IT carve-out and invest further in innovation and new product development. We are working with Rosemont to achieve its M&A ambitions by sourcing and evaluating potential targets that complement Rosemont’s current product portfolio.

Inflexion brings a number of strengths to our business, firstly a challenging mindset stimulating management to think about being more ambitious. They are agile but approachable. There is access to additional funding and to their network which is important in identifying opportunities on the M&A front. M&A is an area that I could not have contemplated without Inflexion.

Howard Taylor,

CEO, Rosemont Pharmaceuticals